Press Releases and Blog
Blog
Senator Rand Paul Sounds the Alarm on Legislation Targeting Pharmacy Benefits that will Actually Increase Prescription Drug Prices
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case
New Brookings Analysis Concludes Legislation Targeting Pharmacy Benefit Companies Will Not Lower Prescription Drug Costs and Actually Weakens Negotiating Power Against Big Pharma
In case you missed it, the Brookings Institution released a new analysis, “A Brief Look At Current Debates About Pharmacy Benefit Managers,” which provides an
ICYMI: PCMA Rx Research Corner Blog Post: Dr. Lawton Robert Burns Sheds Light on the Role of PBMs
“PBMs promote competition in healthcare and help to reduce prices,” said Lawton Robert Burns Hot Off the Presses: University of Pennsylvania Wharton School professor Lawton
ICYMI: Pharmacy Benefit Managers Are Not To Blame For Rising Drug Prices
PCMA Urges Congress to Listen to Constituents and Address Rising Drug Prices In case you missed it, JC Scott, president and CEO of the Pharmaceutical
ICYMI: Costello: Targeting Pharmacy Benefits Would Raise Drug Costs
In case you missed it, former U.S. Representative for Pennsylvania’s 6th Congressional District Ryan Costello discusses how recent legislation targeting pharmacy benefit companies will raise
ICYMI: A World Without Pharmacy Benefit Companies? Ask the Department of Labor
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health
Press Releases
PCMA Announces Katie Payne as Senior Vice President, Strategic Communications
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today announced that Katie Payne has been appointed Senior Vice President of Strategic Communications. In her
PCMA Statement on New Milliman Report on Insulin Coverage in Medicare Part D
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on a new Milliman report on insulin coverage in Medicare Part D.
PCMA Supports Legislation to Direct the FTC to Examine the Entire Prescription Drug Supply and Payment Chain on Rx Costs
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on S. 1388, the “Prescription Drug Pricing for the People Act.” PCMA,
PCMA Statement on Medicare Part D Final Rule
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the final Contract Year 2023 Policy and Technical Changes to the
PCMA Calls for Expanding COVID-19 “Test to Treat” Protocols to Include Pharmacists
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today issued the following statement supporting the policy of one-stop COVID-19 testing and
New PCMA Podcast Highlights Importance of PBMs
(Washington, D.C.) — The Pharmaceutical Care Management Association’s (PCMA) podcast, The Pharmacy Benefit, today released a new episode, “The Importance of PBMs in Health Care Costs,” which highlights the
Webinar Highlights Big Pharma’s Rising Launch Prices and Cost-Saving Value of Pharmacy Benefit Companies
Last month, the IQVIA Institute held a webinar, “The Use of Medicines in the U.S. 2023.” Panelists highlighted how big drug companies set the price of
Economic Experts Sound Alarm On Misguided Legislation Targeting Pharmacy Benefit Companies
Economists Explain Policies Restricting Pharmacy Benefits Will Lead To Higher Costs, Less Competition, And Fewer Choices For Employers In case you missed it, Joe Grogan,
New Episode Of “The Pharmacy Benefit” Podcast Discusses Why We Need Competition To Drive Down Prescription Drug Costs
Alex Brill and Angela Banks Dive into the Critical Need for Competition, Big Drug Companies’ Abuse of the Patent System, and Biosimilar Adoption In case
Small And Mid-Sized Employers Rely On Spread Pricing For Predictable, Fixed Pricing
Pharmacy Benefit Companies Provide Employers with Coverage Choices and Flexibilities t hat Work for their Unique Needs Pharmacy benefit companies offer employers, including small and
Rebates Secured by Pharmacy Benefit Companies Result in Savings for Patients and Employers — and Have No Correlation to High Drug Prices
Pharmacy benefit companies push big drug companies for price concessions through rebates. 99.6 percent of rebates get passed directly to Medicare Part D plans, and
Expert Witness and Lawmakers Highlight Root Cause of High Rx Prices: Big Pharma’s Anti-Competitive Tactics
Hearing Confirms Big Drug Companies Would Benefit from Misguided Proposals Targeting Pharmacy Benefits This week, the U.S. House Committee on Oversight and Accountability held a
Pharmacy Benefit Companies Lower Rx Costs and Provide Critical Flexibility for Employers and Labor Unions
The evidence is clear: pharmacy benefit companies lower prescription drug costs for employers, labor union plans, taxpayers, and patients. While big drug companies push a
Expert Witness and Lawmakers Highlight Root Cause of High Rx Costs – Big Drug Companies’ Anti-Competitive Tactics
Last week, the U.S. House Ways and Means Committee Health Subcommittee held a hearing on “Why Health Care is Unaffordable: Anticompetitive and Consolidated Markets.” During
Pharmacy Benefit Companies Highlight Critical Role of Making Insulin Affordable and Accessible for All Americans at Senate Hearing
Pharmacy Benefit Companies Negotiate with Big Drug Companies to Lower Prescription Drug Costs for Patients and Families Last week, the U.S. Senate Health, Education, Labor
Market Forces Working to Lower Insulin Costs
Encouraging Signs that the Insulin Affordability Battle is Improving This week, as congressional hearings focus on access to affordable insulins, it should be recognized that